Emerging Therapies and Personalized Medicine in Lymphomas

Dear Colleagues,

Lymphomas comprise a diverse group of hematologic malignancies, affecting patients of all ages, races, and socioeconomic statuses. Non-Hodgkin lymphomas constitute approximately 4.3% of new cancer cases in the United States, with an estimated 81,560 new cases in 2021, while Hodgkin lymphoma comprises 0.5% of all new cancer cases, with an estimated 8830 new cases in 2021. The diagnosis and classification of lymphomas require an adequate biopsy specimen and an expert pathologic review, given the different management strategies for individual lymphoma subtypes. Clinical presentation is highly heterogeneous, with the majority of lymphomas considered to be clinically aggressive.

With a better understanding of disease biology, there has been a tremendous advancement in the treatment landscape of both Hodgkin and non-Hodgkin lymphomas. The advent of small molecule-targeted therapies, antibody–drug conjugates, chimeric antigen receptor T cells (CART) and bispecific T cell engager (BITe) antibodies have revolutionized the treatment approach in the field of lymphoma, leading to improved outcomes for these patients. In this issue, we will focus on the current landscape and emerging therapies in Hodgkin and non-Hodgkin lymphomas and provide a personalized management approach for these patients in light of these advances.

Dr. Narendranath Epperla
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.